In this randomized phase II study, we evaluated the efficacy and safety of anastrozole plus UFT versus anastrozole alone as neoadjuvant therapy for ER-positive, HER2-negative postmenopausal breast cancer. Here, ESR1 is linked to breast carcinoma.